摘要
目的:观察EB病毒(EBV)潜伏膜蛋白2A(LMP2A)在鼻咽癌(NPC)患者肿瘤组织中的表达,探讨采用LMP2A作为靶抗原进行NPC免疫治疗的可行性。方法:采用SP免疫组织化学方法,检测40例NPC组织及38例鼻咽黏膜慢性炎症组织标本LMP2A的表达。结果:40例NPC标本中36例LMP2A表达阳性(90.0%);LMP2A的表达与NPC病理分化程度无明显相关性。38例鼻咽黏膜慢性炎症组织标本中33例LMP2A阴性反应,5例阳性反应。鼻咽黏膜慢性炎组织与NPC组织中LMP2A阳性表达率间差异存在统计学意义。结论:在不同病理分化程度的NPC肿瘤组织中LMP2A均可广泛表达,在正常鼻咽组织细胞中基本不表达。采用LMP2A作为靶抗原诱导机体特异性细胞免疫反应杀伤NPC肿瘤细胞具一定可行性。
Objective:To investigate the expression of Epstein-Barr Virus (EBV) latent membrane protein 2A (LMP2A) in tumor tissues of nasopharyngeal cancer (NPC) and discuss the possibility (feasibility) that LMP2A was selected (to select <of selecting> LMP2A ) as a target antigen in immunologic treatment of NPC.Method:The expression of EBV LMP2A was detected in the specimens of 40 patients with NPC and 38 cases with nasopharyngeal inflammation by S-P immunohistochemical methods.Result:Of the 40 NPC specimens, 36 cases expressed LMP2A. There was no significant relationship between the expression of LMP2A and the histological differentiation of NPC.Thirty-three of the 38 cases with nasopharyngeal inflammation showed negative expression of LMP2A. There was a significant difference of LMP2A expression between NPC and nasopharyngeal inflammation.Conclusion:The expression of EBV LMP2A is confirmed in the NPC specimens,and the negative results are seen in the majority of the inflammation cases.There is a possibility of applying LMP2A target antigen to induce specific immunoreaction to kill tumor cells of NPC.
出处
《临床耳鼻咽喉科杂志》
CSCD
北大核心
2005年第11期484-487,共4页
Journal of Clinical Otorhinolaryngology
基金
江苏省科委"95"攻关课题研究基金资助项目(No:BJ98100)
国家自然科学基金资助项目(No:30170880)
江苏省卫生厅科研基金资助项目(No:H2000336)
江苏省人事厅留学人员科研基金资助项目(No:IA0401)
江苏省分子生物学对外实验室研究基金资助项目(No:K99051)
